These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 27980406

  • 1. Using hyaluronic acid-functionalized pH stimuli-responsive mesoporous silica nanoparticles for targeted delivery to CD44-overexpressing cancer cells.
    Wang Z, Tian Y, Zhang H, Qin Y, Li D, Gan L, Wu F.
    Int J Nanomedicine; 2016; 11():6485-6497. PubMed ID: 27980406
    [Abstract] [Full Text] [Related]

  • 2. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
    Zhang J, Sun Y, Tian B, Li K, Wang L, Liang Y, Han J.
    Colloids Surf B Biointerfaces; 2016 Aug 01; 144():293-302. PubMed ID: 27107383
    [Abstract] [Full Text] [Related]

  • 3. pH-responsive nanoreservoirs based on hyaluronic acid end-capped mesoporous silica nanoparticles for targeted drug delivery.
    Chen C, Sun W, Wang X, Wang Y, Wang P.
    Int J Biol Macromol; 2018 May 01; 111():1106-1115. PubMed ID: 29357289
    [Abstract] [Full Text] [Related]

  • 4. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells.
    Zhao Q, Liu J, Zhu W, Sun C, Di D, Zhang Y, Wang P, Wang Z, Wang S.
    Acta Biomater; 2015 Sep 01; 23():147-156. PubMed ID: 25985912
    [Abstract] [Full Text] [Related]

  • 5. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B, Poudel BK, Ruttala HB, Regmi S, Pathak S, Gautam M, Jin SG, Jeong JH, Choi HG, Ku SK, Yong CS, Kim JO.
    Acta Biomater; 2018 Oct 15; 80():364-377. PubMed ID: 30201431
    [Abstract] [Full Text] [Related]

  • 6. Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.
    Yu M, Jambhrunkar S, Thorn P, Chen J, Gu W, Yu C.
    Nanoscale; 2013 Jan 07; 5(1):178-83. PubMed ID: 23076766
    [Abstract] [Full Text] [Related]

  • 7. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
    Li W, Guo Z, Zheng K, Ma K, Cui C, Wang L, Yuan Y, Tang Y.
    Int J Pharm; 2017 Dec 20; 534(1-2):71-80. PubMed ID: 28958879
    [Abstract] [Full Text] [Related]

  • 8. Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles.
    Yang S, Zhang B, Zhao X, Zhang M, Zhang M, Cui L, Zhang L.
    Int J Mol Sci; 2024 May 20; 25(10):. PubMed ID: 38791591
    [Abstract] [Full Text] [Related]

  • 9. Enzyme-responsive mesoporous silica nanoparticles for tumor cells and mitochondria multistage-targeted drug delivery.
    Naz S, Wang M, Han Y, Hu B, Teng L, Zhou J, Zhang H, Chen J.
    Int J Nanomedicine; 2019 May 20; 14():2533-2542. PubMed ID: 31114189
    [Abstract] [Full Text] [Related]

  • 10. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe3O4 nanoparticles for targeted drug delivery.
    Fang Z, Li X, Xu Z, Du F, Wang W, Shi R, Gao D.
    Int J Nanomedicine; 2019 May 20; 14():5785-5797. PubMed ID: 31440047
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P, Li L, Zhou S, Qiu L, Qian Z, Liu X, Cao X, Zhang H.
    Mater Sci Eng C Mater Biol Appl; 2018 Mar 01; 84():108-117. PubMed ID: 29519418
    [Abstract] [Full Text] [Related]

  • 14. Construction and performance evaluation of pH-responsive oxidized hyaluronic acid hollow mesoporous silica nanoparticles.
    Enyu X, Xinbo L, Xuelian C, Huimin C, Yin C, Yan C.
    Int J Biol Macromol; 2024 Feb 01; 257(Pt 1):128656. PubMed ID: 38065461
    [Abstract] [Full Text] [Related]

  • 15. Tumor-targeting and pH-responsive nanoparticles from hyaluronic acid for the enhanced delivery of doxorubicin.
    Liao J, Zheng H, Fei Z, Lu B, Zheng H, Li D, Xiong X, Yi Y.
    Int J Biol Macromol; 2018 Jul 01; 113():737-747. PubMed ID: 29505869
    [Abstract] [Full Text] [Related]

  • 16. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
    Hakeem A, Zahid F, Zhan G, Yi P, Yang H, Gan L, Yang X.
    Int J Nanomedicine; 2018 Jul 01; 13():1029-1040. PubMed ID: 29497295
    [Abstract] [Full Text] [Related]

  • 17. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
    Wang D, Huang J, Wang X, Yu Y, Zhang H, Chen Y, Liu J, Sun Z, Zou H, Sun D, Zhou G, Zhang G, Lu Y, Zhong Y.
    Biomaterials; 2013 Oct 01; 34(31):7662-73. PubMed ID: 23859657
    [Abstract] [Full Text] [Related]

  • 18. pH and redox dual stimulate-responsive nanocarriers based on hyaluronic acid coated mesoporous silica for targeted drug delivery.
    Lin JT, Du JK, Yang YQ, Li L, Zhang DW, Liang CL, Wang J, Mei J, Wang GH.
    Mater Sci Eng C Mater Biol Appl; 2017 Dec 01; 81():478-484. PubMed ID: 28888000
    [Abstract] [Full Text] [Related]

  • 19. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
    Bagheri E, Alibolandi M, Abnous K, Taghdisi SM, Ramezani M.
    J Mater Chem B; 2021 Feb 15; 9(5):1351-1363. PubMed ID: 33447840
    [Abstract] [Full Text] [Related]

  • 20. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
    Lin CW, Lu KY, Wang SY, Sung HW, Mi FL.
    Acta Biomater; 2016 Apr 15; 35():280-92. PubMed ID: 26853764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.